Dr. Thomas J. Spillane, MD
Medical Oncology (Medical Oncology Physician)
715 Tank Farm Road, Suite C
San Luis Obispo, CA 93401
Who else practices at this address →
San Luis Obispo County includes mental health (55% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Davis School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 860
Licensed in California since 1994, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: University of California, Davis School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license G79734 (first issued 1994; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Marian Regional Medical Center Santa Maria, CA
- French Hospital Medical Center San Luis Obispo, CA
- Adventist Health Sierra Vista San Luis Obispo, CA
- Adventist Health Twin Cities Templeton, CA
Medical groups
- Pacific Central Coast Health Centers (253 clinicians)
- David B. Hammer (123 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 860
- Services billed
- 3,622
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,743 | 649 |
| Established patient office or other outpatient visit, 20-29 minutes | 525 | 370 |
| Established patient office or other outpatient visit, 40-54 minutes | 205 | 136 |
| New patient office or other outpatient visit, 45-59 minutes | 64 | 64 |
| New patient office or other outpatient visit, 60-74 minutes | 49 | 49 |
| New patient office or other outpatient visit, 30-44 minutes | 32 | 32 |
| Established patient office or other outpatient visit, 10-19 minutes | 23 | 21 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | 16 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 58 companies reported 263 payments worth $7,854 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $2,010 |
|---|---|
| Janssen Biotech, Inc. | $549 |
| Exelixis Inc. | $396 |
| Novartis Pharmaceuticals Corporation | $346 |
| Pfizer Inc. | $316 |
| Daiichi Sankyo Inc. | $276 |
| Merck Sharp & Dohme LLC | $272 |
| Adc Therapeutics America, Inc. | $195 |
| Food and Beverage | $6,192 |
|---|---|
| Consulting Fee | $1,650 |
| Education | $12.42 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jul 2, 2025 | Consulting Fee CALQUENCE · Oncology | $1,650 |
| Gilead Sciences, Inc. Nov 26, 2025 | Education Trodelvy · ONC · in-kind Company’s description;4219031;G360;10792206 | $12.42 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $5,500 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
E.r. Squibb & Sons, L.l.c. · Terminated · NCT05780736
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.